TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
TECH

Bio-Techne Corp

Healthcare · Biotechnology

72.40$ +0.1% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Bio-Techne Corp (TECH)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.6% of the shares are freely tradable; institutional investors hold 117.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 117.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 157Mio.

Largest Shareholders

Institutions

Institutions TECH
Name Stake (%) Shares Change (%) Date
BlackRock Inc 7.82 12,264,513 +1.1 03/31/2026
Vanguard Capital Management, LLC 6.49 10,179,709 +0.0 03/31/2026
Morgan Stanley - Brokerage Accounts 5.44 8,532,873 +2.2 03/31/2026
FMR Inc 5.04 7,899,928 +678.3 03/31/2026
HBK INVESTMENTS L P 4.35 6,825,000 +0.0 06/30/2026
Vanguard Portfolio Management, LLC 4.13 6,480,337 +0.0 03/31/2026
State Street Corp 3.74 5,868,396 +1.0 03/31/2026
Geode Capital Management, LLC 3.26 5,112,420 +3.7 03/31/2026
Maverick Capital Ltd 3.02 4,739,721 +23.1 03/31/2026

Funds

Funds TECH
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 3.18 4,984,593 +0.3 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings TECH
Person Role Shares Value As of Type
Hippel James CFO 170,183 12,321,249 $ Aug 15, 2026 direct
Kelderman Kim Chief Executive Officer 82,762 5,991,969 $ Aug 15, 2026 direct
Geist William PRESIDENT, PROTEIN SCIENCES 24,943 1,805,873 $ Aug 15, 2026 direct
Bohnen Shane SVP - General Counsel 10,360 750,064 $ Aug 15, 2026 direct
Crouse Steven C. President - Diag & Spatial Bi 10,237 741,159 $ Aug 15, 2026 direct
Herr Amy E. Director 576 41,702 $ Aug 15, 2026 indirect

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Aug 15, 2026 Kelderman Kim Chief Executive Officer Other 10,821 72.40 783,440
Aug 15, 2026 Kelderman Kim Chief Executive Officer Other 21,470 0.00
Aug 15, 2026 Hippel James CFO Other 4,310 72.40 312,044
Aug 15, 2026 Hippel James CFO Other 9,779 0.00
Aug 15, 2026 Geist William PRESIDENT, PROTEIN SCIENCES Other 1,976 72.40 143,062
Aug 15, 2026 Geist William PRESIDENT, PROTEIN SCIENCES Other 6,416 0.00
Aug 15, 2026 Bohnen Shane SVP - General Counsel Other 1,343 72.40 97,233
Aug 15, 2026 Bohnen Shane SVP - General Counsel Other 4,350 0.00
Aug 15, 2026 Crouse Steven C. President - Diag & Spatial Bi Other 1,947 72.40 140,963
Aug 15, 2026 Crouse Steven C. President - Diag & Spatial Bi Other 5,423 0.00
Aug 15, 2026 Herr Amy E. Director Other 213 72.40 15,421
Aug 15, 2026 Herr Amy E. Director Other 589 0.00
Jul 29, 2026 Hippel James CFO Other 51,024 72.03 3,675,259
Jul 29, 2026 Hippel James CFO Other 62,068 47.60 2,954,437
Jul 28, 2026 Kelderman Kim Chief Executive Officer Other 28,686 72.07 2,067,400
Jul 28, 2026 Kelderman Kim Chief Executive Officer Other 35,000 47.60 1,666,000
Jul 23, 2026 Bohnen Shane SVP - General Counsel Other 344 71.77 24,689
Jul 23, 2026 Bohnen Shane SVP - General Counsel Other 448 47.60 21,325

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?